Navigation Links
Cadence Pharmaceuticals Completes $86.6 Million Private Placement of Common Stock
Date:2/19/2009

t Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit www.cadencepharm.com.

Forward-Looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Cadence that any of its plans will be achieved. Actual results may also differ from those projected in forward-looking statements due to risks and uncertainties that exist in the Company's operations and business environments, including the possible need to raise additional capital and the possibility that Cadence's share price may decline after the transaction is closed. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

    Contacts:   William R. LaRue
      
'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Cadence Pharmaceuticals Chief Medical Officer James Breitmeyer to Present at JMP Securities Healthcare Focus Conference
2. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
3. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York
6. Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIO CEO and Investor Conference in New York City
8. Cadence Pharmaceuticals to Raise $86.6 Million in a Private Placement of Common Stock
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
11. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... 28, 2015 The California-based leading wig ... every customer shopping on UniWigs during the Easter Holidays ... a big promotion on April Fools’ Day. , As ... just around the corner. Easter Festival, with religious origins ... a major holiday after Christmas. The best wig provider, ...
(Date:3/28/2015)... India Network visitor health insurance ... to all visitors who purchase the plan before arrival ... encouraged to purchase the insurance program as soon as ... coverage for pre-existing medical conditions. Parents and grandparents traveling ... conditions with serious consequences to their health. Many visitors ...
(Date:3/28/2015)... March 28, 2015 Centurion Service Group will ... on Thursday, April 2 at their Las Vegas warehouse, located ... 89081. The sale, which consists of equipment from hospitals and ... at 9 a.m. PDT. , Buyers will find items ... equipment. “We are a one-stop-shop,” said Erik Tivin, CEO of ...
(Date:3/28/2015)... Vegas, NV (PRWEB) March 28, 2015 ... experiences re-injury, according to research presented today at the ... Specialty Day. The study examined the long term success ... , “We examined survey data from 242 patients ... lead author Justin P. Roe, MBBS, FRACS, from North ...
(Date:3/28/2015)... Vegas, NV (PRWEB) March 28, 2015 ... may not be necessary, according to research presented today ... AOSSM ) Specialty Day. , “Our study compared results ... 25 who underwent an additional glenohumeral joint capsule release ... commented George Murrell MD, PhD, lead author from St. ...
Breaking Medicine News(10 mins):Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Medical Equipment Auction to Take Place in North Las Vegas 2Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2
... But 10-year study also showed having enough folate in diet might ... study has found that men who took folic acid supplements faced ... didn,t take the supplements. , But the incidence of prostate cancer ... simply got adequate amounts of folate in their diet, according to ...
... permits precise tuning of a gene,s expression in a cell, ... the gene,s role in normal and abnormal cellular function. , ... feedback loop in the synthetic gene circuit, a concept similar ... scientists at The University of Texas M. D. Anderson Cancer ...
... 30th annual PROJECT HEALTHY LIVING, sponsored by WXYZ-TV/Channel ... Monday, March 16 through Thursday, May 14 at more ... six metro Detroit counties. Project Healthy Living provides free ... Free tests at all sites include blood pressure, height ...
... 10 Gundersen Lutheran is the first in the ... the National Quality Measures for Breast Centers(TM) (NQMBC) Program. ... highest level of quality breast health care. It,s the ... Lutheran Health System, based in La Crosse, Wis., a ...
... family doctor says stress can take huge tollBLOOMINGTON, Ind., ... when you read the daily stock market report is ... prove troublesome or even deadly, according to Dr. Michael ... health for middle-aged Americans.As the economic crisis has worsened, ...
... 10 Insmed Inc. (Nasdaq: INSM ), ... announced that the U.S. Food and Drug Administration (FDA) ... to the agency,s position on allowing patients with Amyotrophic ... IPLEX(TM) under an Investigational New Drug (IND) application. ...
Cached Medicine News:Health News:Folic Acid Supplements Raise Prostate Cancer Risk 2Health News:Folic Acid Supplements Raise Prostate Cancer Risk 3Health News:Synthetic gene circuit allows precise dosing of gene expression 2Health News:Synthetic gene circuit allows precise dosing of gene expression 3Health News:Project Healthy Living to be Held March 16 to May 14th 2Health News:Gundersen Lutheran Breast Center Earns Top National Honor 2Health News:Is the Recession Killing You? It May Be 2Health News:Insmed Announces FDA Issues Statement Regarding Position on Allowing Patients With ALS Access to IPLEX(TM) Under an IND 2
(Date:3/27/2015)... Report Details  New ... companies  What does the future hold for ... Visiongain,s brand new report shows you potential revenues to ... Our 242-page report provides 185 tables, charts, and ... and the future market prospects. Our new study lets ...
(Date:3/27/2015)...   Hospira, Inc. (NYSE: HSP ... world,s leading provider of injectable drugs and infusion ... of biosimilarity of its proposed biosimilar, Epoetin Hospira, ... conditionally approved name of RETACRIT™, compared to the ... data were presented at the National Kidney Foundation ...
(Date:3/27/2015)... -- Concord Medical Services Holdings Limited ("Concord Medical" ... leading specialty hospital management solution provider and operator ... imaging centers in China , ... under which Concord Medical Services (International) Pte Ltd, ... to acquire the Fortis Surgical Hospital from Fortis ...
Breaking Medicine Technology:Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 2Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 3
... These modified battery ... power supplies for GENIE ... to produce very specific ... reproducibility than laboratory power ...
... These modified battery chargers ... supplies for GENIE blotters. ... produce very specific voltages, ... than laboratory power supplies. ...
Power Supply E865 is ideal for electrophoresis and semi-dry blotting applications. The electrical leads from Hoefer Gel apparatus are fully compatible with this new E865 power supply and there is no ...
Inquire...
Medicine Products: